Global websites

Global: English

Local websites

Germany: Deutsch
Japan: 日本語
Netherlands: Nederlands
Spain: Español
United Kingdom: English
United States: English

Newsroom

News

November 28, 2023

The latest

argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

Amsterdam, the Netherlands

argenx SE today announced topline results from the ADVANCE-SC study evaluating VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with primary immune thrombocytopenia (ITP). The study did not meet the primary endpoint of a sustained platelet count response in chronic ITP patients.

argenx Stories

See where we started — and where we’re going — as we chart a new course together in immunology.

Press Releases

November 28, 2023

argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

November 16, 2023

argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis

November 1, 2023

argenx to Present at Upcoming Investor Conferences

November 1, 2023

argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

Download assets

Get photos, fact sheets, illustrations and more.

Join the team

Dare to do more with a thriving career at argenx.

Find your career

Follow us

Get the latest news and info via our social media channels.

argenx on LinkedIn